The estimated Net Worth of Anastasios Gianakakos is at least $14.1 Milión dollars as of 2 July 2020. Anastasios Gianakakos owns over 5,000 units of MyoKardia stock worth over $4,300,729 and over the last 9 years Anastasios sold MYOK stock worth over $9,847,365.
Sign up
Anastasios Gianakakos MYOK stock SEC Form 4 insiders trading
Anastasios has made over 49 trades of the MyoKardia stock since 2015, according to the Form 4 filled with the SEC. Most recently Anastasios sold 5,000 units of MYOK stock worth $469,900 on 2 July 2020.
The largest trade Anastasios's ever made was selling 32,988 units of MyoKardia stock on 25 July 2017 worth over $494,820. On average, Anastasios trades about 4,189 units every 27 days since 2015. As of 2 July 2020 Anastasios still owns at least 19,122 units of MyoKardia stock.
You can see the complete history of Anastasios Gianakakos stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Anastasios Gianakakos's mailing address?
Anastasios's mailing address filed with the SEC is C/O MYOKARDIA, INC., 1000 SIERRA POINT PARKWAY, BRISBANE, CA, 94005.
Insiders trading at MyoKardia
Over the last 9 years, insiders at MyoKardia have traded over $313,807,381 worth of MyoKardia stock and bought 2,317,816 units worth $42,556,877 . The most active insiders traders include Sanofi, Kevin P Starr a Rock Ventures Ii, L.P.Third.... On average, MyoKardia executives and independent directors trade stock every 16 days with the average trade being worth of $21,462,936. The most recent stock trade was executed by Anastasios Gianakakos on 2 July 2020, trading 5,000 units of MYOK stock currently worth $469,900.
What does MyoKardia do?
MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA.
What does MyoKardia's logo look like?
Complete history of Anastasios Gianakakos stock trades at MyoKardia
MyoKardia executives and stock owners
MyoKardia executives and other stock owners filed with the SEC include:
-
Tassos Gianakakos,
President, Chief Executive Officer, Director -
William Fairey,
Executive Vice President and Chief Commercial Officer -
Robert McDowell,
Chief Scientific Officer -
Jake Bauer,
Chief Business Officer -
Taylor Harris,
Chief Financial Officer -
Mark Perry,
Non-Executive Independent Chairman of the Board -
Mary Cranston,
Independent Director -
Sunil Agarwal,
Independent Director -
Wendy Yarno,
Independent Director -
David Meeker,
Independent Director -
Kimberly Popovits,
Independent Director -
Michelle Corral,
IR Contact Officer -
Denelle Waynick,
General Counsel, Corporate Secretary -
Rock Ventures Ii, L.P.Third...,
-
Sanofi,
10% owner -
Eric Topol,
Director -
Anastasios Gianakakos,
President and CEO -
Joseph Lambing,
See Remarks -
Marc Semigran,
Chief Medical Officer -
Kevin P Starr,
Director -
Steven Chan,
See Remarks -
Charles J Homcy,
Director -
June Lee,
EVP, Chief Development Officer -
Jonathan C Fox,
Chief Medical Officer -
Rock Ventures Iii, L.P.Thir...,
-
Cynthia J Ladd,
General Counsel -
Rock Ventures Ii, L.P.Third...,